The annual AusBiotech conference is a key event to discuss pivotal issues and emerging topics facing the life sciences & biotech industry in Australia, attracting delegates from around the world.
This year, Spruson & Ferguson experts have been involved in developing parts of the programme, particularly the AgriBiotech section, and will feature in two key panel sessions. Find further detail of these below and please reach out to our Key Team Members directly if you would like to connect.
We hope to see you there!
Details: 30 Oct – 1 Nov 2024, Melbourne Convention & Exhibition Centre
Main programme
Practical & legal considerations of deploying AI in the biotech sector – now and future – Friday 1 November, 2.10pm
AI is proving to be a useful time-saver for many industries, but in terms of discovery, development and ultimately intellectual property (IP) ownership in the biotech industry, where are the boundaries and what are the best uses for these developing technologies? Framing the discussion using the recent release of the Australian Government's Voluntary AI Safety Standards, Sylvie will guide the panel through several topical issues:
- what AI is currently being used for in the biotech landscape
- practical challenges of utilising AI in creating or commercialising inventions
- what role can AI play or shape the biotech industry for the next five to ten years?
- positive impacts and/or concerns
- legal challenges associated with protection of AI inventions
- broader legal considerations in using AI.
AgriBiotech & Biosecurity Summit
Panel discussion | Investment for Innovation – Thursday 31 October, 3.35 – 4.50pm
Peter will chair this fascinating panel discussion with investor
perspectives from both the public and private sectors. Panellists
will share their experiences, including what worked, what
didn't, and what surprised them, over the various stages of the
innovation journey, from early-stage R&D to investment and
impact.
Panellists
- Michelle Goldsmith, Chief Executive Officer, Agriculture Victoria Services
- Dr Andrew Kelly, Executive Director, Bio Pacific Partners
- Dr Chris Nave, Managing Director & Managing Partner, Brandon Capital Partners
- Steve Torso, Co-Founder & Managing Director, Wholesale Investor
- Dr Elaine Stead, Principal, Main Sequence
- Rowena Gracey, Director, ARCHIMED